{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:11:01Z","timestamp":1769832661856,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"synAgile Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78145-4","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:04:21Z","timestamp":1730822661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"14","author":[{"given":"William L.","family":"Murch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Spiridigliozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"78145_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/mds.29824","volume":"39","author":"CW Olanow","year":"2024","unstructured":"Olanow, C. W. et al. Continuous levodopa delivery with an intraoral micropump system: an open-label pharmacokinetics and clinical study. Mov. Disord. 39, 945\u2013954 (2024).","journal-title":"Mov. Disord."},{"key":"78145_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/0003-4819-10-2-179","volume":"10","author":"EP Joslin","year":"1936","unstructured":"Joslin, E. P. Diabetes today and tomorrow. Ann. Intern. Med. 10, 179\u2013193 (1936).","journal-title":"Ann. Intern. Med."},{"key":"78145_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.1936.02770340025006","volume":"107","author":"HA Freund","year":"1936","unstructured":"Freund, H. A. & Adler, S. Effects of standard, protamine and crystalline insulin on blood sugar levels. J. Am. Med. Assoc. 107, 573\u2013577 (1936).","journal-title":"J. Am. Med. Assoc."},{"key":"78145_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/bmj.1.6107.204","volume":"1","author":"JC Pickup","year":"1978","unstructured":"Pickup, J. C., Keen, H., Parsons, J. A. & Alberti, K. G. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br. Med. J. 1, 204\u2013207 (1978).","journal-title":"Br. Med. J."},{"key":"78145_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/263797a0","volume":"263","author":"R Langer","year":"1976","unstructured":"Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797\u2013800 (1976).","journal-title":"Nature"},{"key":"78145_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/hrt.53.6.631","volume":"53","author":"MA James","year":"1985","unstructured":"James, M. A., Walker, P. R., Papouchado, M. & Wilkinson, P. R. Efficacy of transdermal glyceryl trinitrate in the treatment of chronic stable angina pectoris. Br. Heart J. 53, 631\u2013635 (1985).","journal-title":"Br. Heart J."},{"key":"78145_CR7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1017\/S0022215100097425","volume":"99","author":"T Rahko","year":"1985","unstructured":"Rahko, T. & Karma, P. Transdermal scopolamine for peripheral vertigo (a double-blind study). J. Laryngol. Otol. 99, 653\u2013656 (1985).","journal-title":"J. Laryngol. Otol."},{"key":"78145_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/clpt.1985.203","volume":"38","author":"JE Rose","year":"1985","unstructured":"Rose, J. E., Herskovic, J. E., Trilling, Y. & Jarvik, M. E. Transdermal nicotine reduces cigarette craving and nicotine preference. Clin. Pharmacol. Ther. 38, 450\u2013456 (1985).","journal-title":"Clin. Pharmacol. Ther."},{"key":"78145_CR9","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz, M. R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26, 1261\u20131268 (2008).","journal-title":"Nat. Biotechnol."},{"key":"78145_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.410180505","volume":"18","author":"JG Nutt","year":"1985","unstructured":"Nutt, J. G., Woodward, W. R. & Anderson, J. L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann. Neurol. 18, 537\u2013543 (1985).","journal-title":"Ann. Neurol."},{"key":"78145_CR11","doi-asserted-by":"publisher","first-page":"S580","DOI":"10.1002\/mds.22037","volume":"23","author":"JG Nutt","year":"2008","unstructured":"Nutt, J. G. Pharmacokinetics and pharmacodynamics of levodopa. Mov. Disord. 23, S580\u2013S584 (2008).","journal-title":"Mov. Disord."},{"key":"78145_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003088-200645020-00001","volume":"45","author":"D Nyholm","year":"2006","unstructured":"Nyholm, D. Pharmacokinetic optimisation in the treatment of Parkinson\u2019s disease: an update. Clin. Pharmacokinet. 45, 109\u2013136 (2006).","journal-title":"Clin. Pharmacokinet."},{"key":"78145_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mds.21060","volume":"22","author":"JG Nutt","year":"2007","unstructured":"Nutt, J. G. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa?. Mov. Disord. 22, 1\u20139 (2007).","journal-title":"Mov. Disord."},{"key":"78145_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/mds.28215","volume":"35","author":"CW Olanow","year":"2020","unstructured":"Olanow, C. W., Calabresi, P. & Obeso, J. A. Continuous dopaminergic stimulation as a treatment for Parkinson\u2019s disease: current status and future opportunities. Mov. Disord. 35, 1731\u20131744 (2020).","journal-title":"Mov. Disord."},{"key":"78145_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ana.410220415","volume":"22","author":"JG Nutt","year":"1987","unstructured":"Nutt, J. G. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann. Neurol. 22, 535\u2013540 (1987).","journal-title":"Ann. Neurol."},{"key":"78145_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410230611","volume":"23","author":"R Kurlan","year":"1988","unstructured":"Kurlan, R. et al. Duodenal and gastric delivery of levodopa in parkinsonism. Ann. Neurol. 23, 589\u2013595 (1988).","journal-title":"Ann. Neurol."},{"key":"78145_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","volume":"15","author":"D Nyholm","year":"2013","unstructured":"Nyholm, D. et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease patients. AAPS J. 15, 316\u2013323 (2013).","journal-title":"AAPS J."},{"key":"78145_CR18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00702-018-1906-0","volume":"125","author":"A Antonini","year":"2018","unstructured":"Antonini, A. & Nitu, B. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease. J. Neural Transm. 125, 1131\u20131135 (2018).","journal-title":"J. Neural Transm."},{"key":"78145_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/mds.28595","volume":"36","author":"T Tsunemi","year":"2021","unstructured":"Tsunemi, T. et al. Intrajejunal infusion of levodopa\/carbidopa for advanced Parkinson\u2019s disease: a systematic review. Mov. Disord. 36, 1759\u20131771 (2021).","journal-title":"Mov. Disord."},{"key":"78145_CR20","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred, J. et al. Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol. Ther. 12, 1937\u20131958 (2023).","journal-title":"Neurol. Ther."},{"key":"78145_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00228-017-2196-4","volume":"73","author":"M Senek","year":"2017","unstructured":"Senek, M. et al. Levodopa\/carbidopa microtablets in Parkinson\u2019s disease: a study of pharmacokinetics and blinded motor assessment. Eur. J. Clin. Pharmacol. 73, 563\u2013571 (2017).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"78145_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cns.12807","volume":"24","author":"D Johansson","year":"2018","unstructured":"Johansson, D. et al. Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. CNS Neurosci. Ther. 24, 439\u2013447 (2018).","journal-title":"CNS Neurosci. Ther."},{"key":"78145_CR23","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/jpm11080720","volume":"11","author":"HM Gr\u00e9tarsd\u00f3ttir","year":"2021","unstructured":"Gr\u00e9tarsd\u00f3ttir, H. M., Widman, E., Johansson, A. & Nyholm, D. Personalized medicine approach in treating Parkinson\u2019s disease, using oral administration of levodopa\/carbidopa microtablets in clinical practice. J. Pers. Med. 11, 720 (2021).","journal-title":"J. Pers. Med."},{"key":"78145_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00002826-198908000-00005","volume":"12","author":"JP Bennett Jr","year":"1989","unstructured":"Bennett, J. P. Jr., Turk, M. & Landow, E. Continuous oral administration of L-dihydroxyphenylalanine (L-DOPA) solution to patients with advanced Parkinson\u2019s disease. Clin. Neuropharmacol. 12, 285\u2013292 (1989).","journal-title":"Clin. Neuropharmacol."},{"key":"78145_CR25","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/mds.27610","volume":"34","author":"CW Olanow","year":"2019","unstructured":"Olanow, C. W. et al. Continuous versus intermittent oral administration of levodopa in Parkinson\u2019s disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. Mov. Disord. 34, 425\u2013429 (2019).","journal-title":"Mov. Disord."},{"key":"78145_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/scientificamerican1279-66","volume":"241","author":"PJ Blackshear","year":"1979","unstructured":"Blackshear, P. J. Implantable drug-delivery systems. Sci. Am. 241, 66\u201373 (1979).","journal-title":"Sci. Am."},{"key":"78145_CR27","doi-asserted-by":"crossref","unstructured":"Hayek, S. M., Yaksh, T. L. & Sharan, A. D. Intrathecal drug delivery systems: functional characteristics and tissue reactivity. In Neuraxial Therapeutics: A Comprehensive Guide, 729\u2013753 (Springer, 2024).","DOI":"10.1007\/978-3-031-39558-1_38"},{"key":"78145_CR28","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511536670","volume-title":"Colloidal Particles at Liquid Interfaces","author":"BP Binks","year":"2006","unstructured":"Binks, B. P. & Horozov, T. S. Colloidal Particles at Liquid Interfaces (Cambridge University Press, 2006)."},{"key":"78145_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0377-0257(98)00094-9","volume":"81","author":"HA Barnes","year":"1999","unstructured":"Barnes, H. A. The yield stress\u2014a review or \u2018\u03c0\u03b1\u03bd\u03c4\u03b1 \u03c1\u03b5\u03b9\u2019\u2014everything flows?. J. Non-Newtonian Fluid Mech. 81, 133\u2013178 (1999).","journal-title":"J. Non-Newtonian Fluid Mech."},{"key":"78145_CR30","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1021\/ma00093a016","volume":"27","author":"G Wanka","year":"1994","unstructured":"Wanka, G., Hoffmann, H. & Ulbricht, W. Phase diagrams and aggregation behavior of poly (oxyethylene)-poly (oxypropylene)-poly (oxyethylene) triblock copolymers in aqueous solutions. Macromolecules 27, 4145\u20134159 (1994).","journal-title":"Macromolecules"},{"key":"78145_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00397-017-1002-7","volume":"56","author":"M Cloitre","year":"2017","unstructured":"Cloitre, M. & Bonnecaze, R. T. A review on wall slip in high solid dispersions. Rheologica Acta 56, 283\u2013305 (2017).","journal-title":"Rheologica Acta"},{"key":"78145_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1122\/1.1879043","volume":"49","author":"DM Kalyon","year":"2005","unstructured":"Kalyon, D. M. Apparent slip and viscoplasticity of concentrated suspensions. J. Rheol. 49, 621\u2013640 (2005).","journal-title":"J. Rheol."},{"key":"78145_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s002800000256","volume":"47","author":"S Berg","year":"2001","unstructured":"Berg, S. et al. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother. Pharmacol. 47, 385\u2013390 (2001).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"78145_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.27091","volume":"63","author":"S Paganoni","year":"2021","unstructured":"Paganoni, S. et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 63, 31\u201339 (2021).","journal-title":"Muscle Nerve"},{"key":"78145_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/jnnp-2022-329024","volume":"93","author":"S Paganoni","year":"2022","unstructured":"Paganoni, S. et al. Effect of sodium phenylbutyrate\/taurursodiol on tracheostomy\/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J. Neurol. Neurosurg. Psychiatry 93, 871\u2013875 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"78145_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1515\/arh-2001-0016","volume":"11","author":"G Roberts","year":"2001","unstructured":"Roberts, G., Barnes, H. & Mackie, C. Using the microsoft excel \u2018solver\u2019 tool to perform non-linear curve fitting, using a range of non-Newtonian flow curves as examples. Appl. Rheol. 11, 271\u2013276 (2001).","journal-title":"Appl. Rheol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78145-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78145-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78145-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:07:32Z","timestamp":1730822852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78145-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78145"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78145-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"At the time of the research and development for this study, all authors were employees and held equity at synAgile Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26826"}}